[go: up one dir, main page]

MX2013010947A - Complejos de galio, composiciones farmacéuticas y métodos de uso. - Google Patents

Complejos de galio, composiciones farmacéuticas y métodos de uso.

Info

Publication number
MX2013010947A
MX2013010947A MX2013010947A MX2013010947A MX2013010947A MX 2013010947 A MX2013010947 A MX 2013010947A MX 2013010947 A MX2013010947 A MX 2013010947A MX 2013010947 A MX2013010947 A MX 2013010947A MX 2013010947 A MX2013010947 A MX 2013010947A
Authority
MX
Mexico
Prior art keywords
methods
complexes
pharmaceutical compositions
gallium complexes
gallium
Prior art date
Application number
MX2013010947A
Other languages
English (en)
Inventor
John K Thottathill
Raymond P Warrel Jr
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc filed Critical Genta Inc
Publication of MX2013010947A publication Critical patent/MX2013010947A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50—Mandelic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención proporciona complejos de galio con un ligando, métodos de realización de complejos, métodos de uso de complejos y composiciones de galio farmacéuticas que comprenden los complejos, en particular estas composiciones adecuadas para la administración oral terapéutica.
MX2013010947A 2011-03-24 2012-03-23 Complejos de galio, composiciones farmacéuticas y métodos de uso. MX2013010947A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161467170P 2011-03-24 2011-03-24
US201161515462P 2011-08-05 2011-08-05
US13/426,877 US20120245135A1 (en) 2011-03-24 2012-03-22 Gallium Complexes, Pharmaceutical Compositions And Methods Of Use
PCT/US2012/030267 WO2012129473A1 (en) 2011-03-24 2012-03-23 Gallium complexes, pharmaceutical compositions and methods of use

Publications (1)

Publication Number Publication Date
MX2013010947A true MX2013010947A (es) 2014-03-12

Family

ID=46877850

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010947A MX2013010947A (es) 2011-03-24 2012-03-23 Complejos de galio, composiciones farmacéuticas y métodos de uso.

Country Status (14)

Country Link
US (2) US20120245135A1 (es)
EP (1) EP2688563B1 (es)
JP (1) JP2014516348A (es)
KR (1) KR20140053874A (es)
CN (1) CN103732221A (es)
AU (1) AU2012230834A1 (es)
BR (1) BR112013024196A2 (es)
EA (1) EA201391384A1 (es)
ES (1) ES2628464T3 (es)
IL (1) IL228439A0 (es)
MX (1) MX2013010947A (es)
SG (1) SG193495A1 (es)
TW (1) TW201309647A (es)
WO (1) WO2012129473A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI735652B (zh) * 2016-09-29 2021-08-11 心悅生醫股份有限公司 麴酸之共晶和/或共熔結晶、包含其之組合物與用途
US10537661B2 (en) 2017-03-28 2020-01-21 DePuy Synthes Products, Inc. Orthopedic implant having a crystalline calcium phosphate coating and methods for making the same
US10537658B2 (en) 2017-03-28 2020-01-21 DePuy Synthes Products, Inc. Orthopedic implant having a crystalline gallium-containing hydroxyapatite coating and methods for making the same
WO2024043867A1 (en) * 2022-08-20 2024-02-29 Sinapu Llc C60 histidine carnosine fumarates and use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315927A (en) * 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
US5258376A (en) 1989-11-22 1993-11-02 Bernstein Lawrence R Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
US6004951A (en) 1989-11-22 1999-12-21 Bernstein; Lawrence Richard Administration of gallium complexes of 3-hydroxy-4-pyrones to provide physiologically active gallium levels in a mammalian individual
US5574027A (en) 1989-11-22 1996-11-12 Bernstein; Lawrence R. Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
US5196412A (en) 1991-03-06 1993-03-23 Johnson Matthey, Inc. Gallium compounds
GB9111689D0 (en) 1991-05-31 1991-07-24 Johnson Matthey Plc Gallium compounds
WO1993002087A1 (en) 1991-07-25 1993-02-04 Les Laboratoires Meram Gallium (iii) complexes, process for their obtention and pharmaceutical compositions containing them
US6203822B1 (en) 1996-09-03 2001-03-20 University Of Iowa Research Foundation Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection
US6582722B1 (en) * 1999-09-13 2003-06-24 Mac Farms, Inc. Amino acid chelate for the effective supplementation of calcium, magnesium and potassium in the human diet
AU2003279067A1 (en) 2002-09-23 2004-04-08 Genta Inc. Tri(alkylcarboxylato) gallium (iii) products and pharmaceutical compositions containing them
US7547454B2 (en) * 2002-11-07 2009-06-16 Shyam K Gupta Hydroxy acid complexes for antiaging and skin renovation
WO2004071425A2 (en) * 2003-02-06 2004-08-26 Bioresponse, Llc The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
CN101296694A (zh) * 2005-11-04 2008-10-29 真塔公司 药物镓组合物和方法
US9103599B2 (en) 2012-08-30 2015-08-11 Wei-Ching Lee Flake and method for reducing temperature of waste heat discharged from air conditioner

Also Published As

Publication number Publication date
EP2688563A1 (en) 2014-01-29
KR20140053874A (ko) 2014-05-08
US20150175631A1 (en) 2015-06-25
AU2012230834A1 (en) 2013-11-07
JP2014516348A (ja) 2014-07-10
EA201391384A1 (ru) 2014-02-28
ES2628464T3 (es) 2017-08-02
CN103732221A (zh) 2014-04-16
US20120245135A1 (en) 2012-09-27
SG193495A1 (en) 2013-10-30
TW201309647A (zh) 2013-03-01
BR112013024196A2 (pt) 2016-12-13
WO2012129473A1 (en) 2012-09-27
EP2688563B1 (en) 2017-03-15
IL228439A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
GB201106750D0 (en) Novel compounds
PH12015501439A1 (en) Oral care products comprising zinc oxide and trimethylglycine
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
MX353216B (es) Productos antitranspirantes con proteinas y sales antitranspirantes.
MX349004B (es) Nuevos compuestos.
GB201118656D0 (en) New compounds
MX366899B (es) Nuevos compuestos.
GB201106743D0 (en) Novel compounds
GEP20186816B (en) Anty il-36r antybodies
EP3072506A4 (en) Carrier for drug delivery and conjugate, composition containing same, and method for administering same
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
PH12014500386A1 (en) Combination treatment for hepatitis c
NZ631144A (en) Compositions and methods for transmucosal absorption
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
PH12013501585A1 (en) Taste-masked oral care compositions
TN2014000322A1 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
PH12015501251A1 (en) Compositions and methods for treating dental caries
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
MX2013009456A (es) Compuestos de azufre aromaticos sustituidos y metodos para su uso.
EA201590732A1 (ru) Диспергируемая таблетка
GEP20156373B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
UA70710U (ru) Способ профилактики рецидивов аллергодерматозов у больных с вторичными иммунодефицитными состояниями